Akari Therapeutics (AKTX) Profit After Tax (2014 - 2026)
Akari Therapeutics (AKTX) posted Profit After Tax of -$14.5 million for Q1 2026, down 172.84% sequentially from -$5.3 million in Q4 2025, and down 290.15% YoY from $7.6 million in Q1 2025.
Akari Therapeutics (AKTX) Profit After Tax (2014 - 2026) Analysis & Trends
Akari Therapeutics (AKTX) has 9 years of Profit After Tax data on file, last reported at -$14.5 million in Q1 2026.
- Quarterly Profit After Tax fell 290.15% year-over-year to -$14.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$28.0 million (up 81.8% YoY) and the FY2025 annual result came in at -$17.3 million, up 12.6% from the prior year.
- Profit After Tax slipped to -$14.5 million in Q1 2026 per AKTX's latest filing, from -$5.3 million in the prior quarter.
- The five-year high for Profit After Tax was $1.0 million in Q1 2023, with the low at -$140.0 million in Q4 2024.
- Average Profit After Tax over 4 years is -$15.2 million, with a median of -$4.1 million recorded in 2023.
- Year-over-year, Profit After Tax sank 3283.11% in 2024 and jumped 96.22% in 2025.
- Akari Therapeutics' Profit After Tax stood at -$4.1 million in 2023, then slumped by 3283.11% to -$140.0 million in 2024, then jumped by 96.22% to -$5.3 million in 2025, then plunged by 172.84% to -$14.5 million in 2026.
- Business Quant data shows AKTX's Profit After Tax at -$14.5 million in Q1 2026, -$5.3 million in Q4 2025, and -$6.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Genmab A | 276,399.99 Bn | 276,398.47 Bn | 831.00 Mn | 53.00 Mn |
| 2 | Akari Therapeutics | 1,217.26 Bn | 1,217.26 Bn | - | -14.46 Mn |
| 3 | BeOne Medicines | 419.38 Bn | 414.59 Bn | 1.35 Bn | 227.36 Mn |
| 4 | Vertex Pharmaceuticals | 126.54 Bn | 119.30 Bn | 2.59 Bn | 1.03 Bn |
| 5 | Pharming | 110.17 Bn | 110.12 Bn | 65.80 Mn | -4.45 Mn |
| 6 | Regeneron Pharmaceuticals | 64.97 Bn | 56.22 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Argenx Se | 56.44 Bn | 56.44 Bn | 1.18 Bn | 378.00 Mn |
| 8 | Alnylam Pharmaceuticals | 40.09 Bn | 37.08 Bn | 959.66 Mn | 205.99 Mn |
| 9 | Revolution Medicines | 37.15 Bn | 37.15 Bn | - | -453.82 Mn |
| 10 | Moderna | 28.64 Bn | 23.43 Bn | -566.00 Mn | -1.34 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -14.46 Mn |
| Dec 31, 2025 | -5.30 Mn |
| Sep 30, 2025 | -6.40 Mn |
| Jun 30, 2025 | -1.90 Mn |
| Mar 31, 2025 | -3.71 Mn |
| Dec 31, 2024 | -139.99 Mn |
| Sep 30, 2024 | -2.90 Mn |
| Jun 30, 2024 | -7.56 Mn |
| Mar 31, 2024 | -5.57 Mn |
| Dec 31, 2023 | -4.14 Mn |
| Sep 30, 2023 | -2.87 Mn |
| Jun 30, 2023 | -4.00 Mn |
| Mar 31, 2023 | 1.00 Mn |
| Dec 31, 2020 | -6.81 Mn |
| Sep 30, 2020 | 913,454.00 |
| Jun 30, 2020 | -7.44 Mn |
| Mar 31, 2020 | -3.75 Mn |
| Dec 31, 2019 | -7.83 Mn |
| Sep 30, 2019 | -2.88 Mn |
| Jun 30, 2019 | -5.95 Mn |